ESC 365 - Opening remarks - Exploring vascular protection in patients with CAD or PAD through the potential of factor Xa inhibition... The COMPASS study.

Open Access

Opening remarks - Exploring vascular protection in patients with CAD or PAD through the potential of factor Xa inhibition... The COMPASS study.

Session: Exploring vascular protection in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) through the potential of factor Xa inhibition... The COMPASS study

Topic: Thrombosis and coagulation

Speaker: Doctor S. Yusuf (Hamilton, CA)

Sponsored by Bayer AG

Event: ESC Congress 2017

Congress Presentation

About the speaker

Doctor Salim Yusuf

Population Health Research Institute, Hamilton (Canada)

26 presentations

0 follower

3 more presentations in this session

Which patients with CAD or PAD are at the highest risk of cardiovascular events... What do the registries teach us.

Speaker: Professor P. Steg (Paris, FR) Professor D. Bhatt (New York, US)

The COMPASS study... Vascular protection with rivaroxaban in patients with CAD or PAD.

Speaker: Doctor S. Connolly (Hamilton, CA) Doctor J. Eikelboom (Hamilton, CA)

Closing remarks - Exploring vascular protection in patients with CAD or PAD through the potential of factor Xa inhibition... The COMPASS study.

Speaker: Doctor S. Connolly (Hamilton, CA)

Access the full session

Exploring vascular protection in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) through the potential of factor Xa inhibition... The COMPASS study

Speakers: Doctor S. Yusuf, Professor P. Steg, Professor D. Bhatt, Doctor S. Connolly, Doctor J. Eikelboom...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by